期刊
FUTURE ONCOLOGY
卷 12, 期 19, 页码 2243-2263出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2016-0042
关键词
bladder; cancer; FGFR1; FGFR3; FGFRs; targeted therapy; urothelial
类别
资金
- Cancer Research UK [C6228/5437, C6228/5433, C6228/A12512]
- Worldwide Cancer Research (AICR) [AICR 06-034]
- Yorkshire Cancer Research [L376PA, L367, L346, L372]
Bladder tumors show diverse molecular features and clinical outcome. Muscle-invasive bladder cancer has poor prognosis and novel approaches to systemic therapy are urgently required. Non-muscle-invasive bladder cancer has good prognosis, but high recurrence rate and the requirement for life-long disease monitoring places a major burden on patients and healthcare providers. Studies of tumor tissues from both disease groups have identified frequent alterations of FGFRs, including mutations of FGFR3 and dysregulated expression of FGFR1 and FGFR3 that suggest that these may be valid therapeutic targets. We summarize current understanding of the molecular alterations affecting these receptors in bladder tumors, preclinical studies validating them as therapeutic targets, available FGFR-targeted agents and results from early clinical trials in bladder cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据